Routine primary prophylaxis for febrile neutropenia with biosimilar granulocyte colony-stimulating factor (nivestim) or pegfilgrastim is cost effective in non-Hodgkin lymphoma patients undergoing curative-intent R-CHOP chemotherapy

• Main Authors: Wang X.J., Tang T., Farid M., Quek R., Tao M., Lim S.T., Wee H.L., Chan A.
• Other Authors: PHARMACY
• Format: Article
• Published: Public Library of Science (PLoS) 2018
• Online Access: http://scholarbank.nus.edu.sg/handle/10635/142662
• Institution: National University of Singapore

10.1371/journal.pone.0148901